# GNPNAT1

## Overview
GNPNAT1 is a gene that encodes the enzyme glucosamine-phosphate N-acetyltransferase 1, which is a key component of the hexosamine biosynthetic pathway. This enzyme is categorized as an acetyltransferase and is responsible for the acetylation of glucosamine-6-phosphate, a critical step in the synthesis of UDP-N-acetylglucosamine. UDP-N-acetylglucosamine is a vital substrate for glycosylation processes, which are essential for protein folding, cell signaling, and membrane stability. The activity of GNPNAT1 is primarily localized in the cytoplasm, where it plays a significant role in maintaining cellular homeostasis and influencing various cellular pathways. The gene's expression and function have been linked to several cancers, including lung adenocarcinoma, breast cancer, and urinary bladder cancer, where it serves as a potential prognostic marker and therapeutic target (Cui2022Identification; Zheng2020Independent; Li2023Risk).

## Function
GNPNAT1 encodes the enzyme glucosamine-phosphate N-acetyltransferase 1, which plays a critical role in the hexosamine biosynthetic pathway. This enzyme is responsible for catalyzing the acetylation of glucosamine-6-phosphate, a key step in the production of UDP-N-acetylglucosamine. UDP-N-acetylglucosamine is an essential substrate for glycosylation processes, which are vital for proper protein folding, cell signaling, and maintaining membrane stability. These processes are crucial for cellular homeostasis and the overall development of the organism.

GNPNAT1 is active in the cytoplasm, where it contributes to the regulation of various cellular functions. By facilitating the biosynthesis of UDP-N-acetylglucosamine, GNPNAT1 indirectly influences numerous cellular pathways and processes, including those involved in the structural integrity of cells and the modulation of signaling pathways. The enzyme's activity is essential for the proper functioning of glycosylation, which impacts a wide range of biological processes and is necessary for the maintenance of healthy cellular and organismal physiology.

## Clinical Significance
GNPNAT1 is implicated in several cancers, including lung adenocarcinoma (LUAD), where it is highly expressed in tumor tissues and associated with poor prognosis. High GNPNAT1 expression is linked to shorter overall survival, disease-specific survival, and progression-free survival in LUAD patients, making it a potential independent prognostic biomarker (Zheng2020Independent). GNPNAT1 is also involved in immune cell infiltration and is correlated with mutations in genes such as KRAS, EGFR, STK11, and TP53, which are common in LUAD (Zheng2020Independent).

In breast cancer, GNPNAT1 is associated with poor survival outcomes, including shorter overall survival, recurrence-free survival, and metastasis-free survival. Its expression is linked to tumor-infiltrating immune cells, such as CD8+ T cells and macrophages, and its knockdown impairs breast cancer cell proliferation (Li2023Risk).

GNPNAT1 is also overexpressed in urinary bladder cancer (UBC), where it is associated with higher tumor grade and stage, suggesting a role in UBC aggressiveness (Cui2022Identification). These findings highlight GNPNAT1's potential as a prognostic marker and therapeutic target in various cancers.


## References


[1. (Cui2022Identification) Yangyan Cui, Hanyi Feng, Jiakuan Liu, Jiajun Wu, Rujian Zhu, Ruimin Huang, and Jun Yan. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer. Frontiers in Molecular Biosciences, September 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.1009168, doi:10.3389/fmolb.2022.1009168. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.1009168)

[2. (Zheng2020Independent) Xiangyu Zheng, Yongwei Li, Chao Ma, Jinjun Zhang, Yanmin Zhang, Zongqiang Fu, and Huan Luo. Independent prognostic potential of gnpnat1 in lung adenocarcinoma. BioMed Research International, 2020:1â€“16, October 2020. URL: http://dx.doi.org/10.1155/2020/8851437, doi:10.1155/2020/8851437. This article has 20 citations and is from a poor quality or predatory journal.](https://doi.org/10.1155/2020/8851437)

[3. (Li2023Risk) Chunzhen Li, Shu Yu, Jie Chen, Qianshan Hou, Siyi Wang, Cheng Qian, and Shulei Yin. Risk stratification based on dna damage-repair-related signature reflects the microenvironmental feature, metabolic status and therapeutic response of breast cancer. Frontiers in Immunology, March 2023. URL: http://dx.doi.org/10.3389/fimmu.2023.1127982, doi:10.3389/fimmu.2023.1127982. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2023.1127982)